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To investigate the role of Toll-like receptor (TLR)9 in the immune response to mycobacteria 
as well as its cooperation with TLR2, a receptor known to be triggered by several major 
mycobacterial ligands, we analyzed the resistance of TLR9
 
 
 
/
 
 
 
 as well as TLR2/9 double 
knockout mice to aerosol infection with 
 
Mycobacterium tuberculosis
 
. Infected TLR9
 
 
 
/
 
 
 
 but 
not TLR2
 
 
 
/
 
 
 
 mice displayed defective mycobacteria-induced interleukin (IL)-12p40 and 
interferon (IFN)-
 
 
 
 responses in vivo, but in common with TLR2
 
 
 
/
 
 
 
 animals, the TLR9
 
 
 
/
 
 
 
 
mice exhibited only minor reductions in acute resistance to low dose pathogen challenge. 
When compared with either of the single TLR-deficient animals, TLR2/9
 
 
 
/
 
 
 
 mice displayed 
markedly enhanced susceptibility to infection in association with combined defects in 
proinflammatory cytokine production in vitro, IFN-
 
 
 
 recall responses ex vivo, and altered 
pulmonary pathology. Cooperation between TLR9 and TLR2 was also evident at the level of 
the in vitro response to live 
 
M. tuberculosis
 
, where dendritic cells and macrophages from 
TLR2/9
 
 
 
/
 
 
 
 mice exhibited a greater defect in IL-12 response than the equivalent cell 
populations from single TLR9-deficient animals. These findings reveal a previously 
unappreciated role for TLR9 in the host response to 
 
M. tuberculosis
 
 and illustrate TLR 
collaboration in host resistance to a major human pathogen.
 
Toll-like receptors (TLRs) are thought to play
a critical role in both innate resistance and the
initiation of adaptive immunity to infectious
agents (1, 2). TLRs are known to recognize
distinct molecular structures on microbes, and
in several cases (e.g., recognition of viruses by
TLR3, TLR7, TLR8, and TLR9), different
sets of TLRs have been associated with the
response to different classes of microorganisms
(1). Although the available evidence suggests
that multiple rather than single TLRs are re-
quired for innate defense against most patho-
gens (for review see reference 2), it is not clear
how signals from different TLRs are orchestrated
in generating a protective response. In particular,
there is controversy as to whether at the in
vivo level multiple TLR interactions are required
to trigger individual effector elements or whether
TLR cooperation stems from the interaction
of distinct effector mechanisms, each triggered
by individual TLRs.
TLR signaling has been postulated to have
a major involvement in the regulation of host
resistance to 
 
Mycobacterium tuberculosis
 
 (3, 4), an
important human pathogen that infects over
one third of the world’s population (5). Immu-
nological control of 
 
M. tuberculosis
 
 infection
has been shown to depend on Th1 CD4
 
 
 
 T
cells as well as TNF, IFN-
 
 
 
, and IL-12 (6–14).
The latter cytokine, produced largely by APCs
such as DCs and macrophages, is thought to
function in mycobacterial immunity by both
inducing and maintaining the Th1-mediated
IFN-
 
 
 
 response (8, 9, 15). 
 
M. tuberculosis
 
 as well
as other mycobacteria contain well-characterized
TLR ligands that are potent in vitro stimuli of a
number of proinflammatory cytokines, includ-
ing TNF and IL-12 (16–19). A role for TLR
signaling in host resistance to 
 
M. tuberculosis
 
 is
further supported by the observation that mice
deficient in MyD88, a major adaptor molecule
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required for signaling events by most TLR/IL-1R family
members, show greatly enhanced susceptibility to aerosol in-
fection with the pathogen, equivalent to that observed with
IFN-
 
 
 
–deficient mice (20, 11). Infected MyD88
 
 
 
/
 
 
 
 animals,
in addition to their loss of resistance, display impaired proin-
flammatory cytokine synthesis, which was found to correlate
with decreased nitric oxide synthase 2 expression and dimin-
ished IFN-
 
 
 
 synthesis (20). In addition, MyD88-deficient
APCs display a marked reduction in the synthesis of IL-12,
TNF, and nitric oxide when exposed to 
 
M. tuberculosis
 
 in
vitro (21, 22).
Although MyD88 appears to play a major role in resis-
tance to 
 
M. tuberculosis
 
, it has been difficult to attribute this
requirement to the function of a single TLR. Thus, mice
deficient in TLR2, TLR4, TLR6, IL-1, or IL-18, although
in some cases displaying specific defects in antimycobacterial
responses, exhibit only minor increases in susceptibility to
low dose aerogenic challenge (23–28). For example, 
 
M. tu-
berculosis
 
–infected TLR2
 
 
 
/
 
 
 
 mice, although showing defec-
tive granuloma formation, display only a small elevation in
pulmonary bacterial loads late in infection and survive for at
least 150 d (28). Interestingly, however, when infected with
unconventionally high doses of 
 
M. tuberculosis
 
, TLR2
 
 
 
/
 
 
 
 but
not TLR4
 
 
 
/
 
 
 
 mice exhibit greatly enhanced susceptibility
compared with WT animals (23, 24). This loss in resistance
is accompanied by alterations in proinflammatory cytokine
and nitric oxide synthase 2 expression as well as the pul-
monary granulomatous response (28). TLR2 also has been
shown to play an important role in the regulation of myco-
bacterial-induced cytokine production by APCs in vitro (23,
28–30). Nevertheless, it is difficult to reconcile this evidence
for TLR2 involvement with the minimal loss in resistance
consistently observed in TLR2
 
 
 
/
 
 
 
 mice challenged with low
level physiological doses of 
 
M. tuberculosis
 
.
One interpretation of the above findings is that host re-
sistance to 
 
M. tuberculosis
 
 depends on a previously unevalu-
ated TLR–ligand interaction. TLR9 is one such TLR/IL-
1R family member whose involvement in control of 
 
M.
tuberculosis
 
 infection has never been formally addressed. TLR9
was initially described as recognizing unmethylated CpG
motifs in bacterial and viral DNA (31, 32) and was shown to
be responsible for the immunostimulatory effects of these
nucleic acids. In this regard, it is of interest that the original
demonstration of the adjuvant properties of DNA emerged
from studies on 
 
Mycobacterium bovis
 
 (bacillus of Calmette and
Guerin [BCG]) (33) and that DNA from 
 
M. tuberculosis
 
 as
well as other mycobacteria has subsequently been shown to
contain highly immunostimulatory CpG motifs (34–37).
TLR9 is known to be localized in endosomes as well as
phagolysosomes, where it could be triggered by mycobacte-
rial DNA after uptake of the pathogen (38–41). For these
reasons we considered TLR9 to be an important candidate
pattern-recognition receptor that might account for the
MyD88 dependency of host resistance to 
 
M. tuberculosis
 
.
In this study, we show that DNA from 
 
M. tuberculosis
 
 is
indeed a potent stimulus of TLR9-dependent proinflamma-
tory cytokine production by both DCs and macrophages and
that the in vitro responses of these cells to live mycobacteria
are also partially dependent on TLR9. In addition, our data
indicate that TLR9 plays an important role in the regulation
of the mycobacteria-induced Th1 responses during 
 
M. tuber-
culosis
 
 infection in vivo. Finally, we demonstrate that mice
doubly deficient in TLR9 and TLR2 show enhanced sus-
ceptibility to 
 
M. tuberculosis
 
 not observed in mice lacking
either TLR2 or TLR9 alone. Taken together, these data
reveal a role for TLR9 in the immune response to 
 
M. tuber-
culosis
 
 and provide an important example of TLR collaboration
in host resistance to infection.
 
RESULTS
DNA from 
 
M. tuberculosis
 
 induces proinflammatory cytokine 
responses through a TLR9-dependent pathway
 
To assess whether TLR9 plays a role in 
 
M. tuberculosis
 
 in-
fection, we first asked if the stimulation of proinflammatory
responses by mycobacterial DNA documented in previ-
ous studies (33–37) depends on this TLR as would be
predicted. As shown in Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20051782/DC1, puri-
fied DNA from 
 
M. tuberculosis
 
, BCG, or 
 
Escherichia coli
 
stimulated IL-12p40 production by splenic CD11c
 
 
 
 DCs
from WT mice. Importantly, this response was found to be
TLR9-dependent as was 
 
M. tuberculosis
 
 DNA–induced IL-
12p40, TNF, and IFN-
 
 
 
 production by BM-derived DCs
(BMDCs; Figs. S1, B and C, and S3) and TNF and IL-6
synthesis by BM-derived macrophages (BMM; Fig. S1, D
and E). In keeping with previously published data demon-
strating a requirement for endosomal acidification in im-
mune stimulation by CpG oligonucleotides (42), the re-
sponse of splenic DCs to mycobacterial DNA was found
to be inhibited by chloroquine treatment (not depicted).
Taken together, these results indicate that mycobacterial
DNA is a potent stimulus for TLR9-dependent cytokine
production by murine APCs.
 
The in vitro IL-12 response of APCs to 
 
M. tuberculosis
 
 bacilli 
is regulated by both TLR9 and TLR2, whereas TNF 
is controlled primarily by TLR2
 
Having demonstrated TLR9-dependent proinflammatory re-
sponses to mycobacterial DNA, we next asked whether
TLR9 regulates cytokine production stimulated by live 
 
M.
tuberculosis
 
 in freshly isolated splenic DCs. In addition, we si-
multaneously assessed the involvement of TLR2 because this
receptor has previously been shown to influence proinflam-
matory cytokine production by BM-derived APC popula-
tions in response to 
 
M. tuberculosis
 
 infection (23, 28, 43).
As shown in Fig. 1 A, live 
 
M. tuberculosis
 
 induced IL-
12p40 secretion by splenic DCs in a dose-dependent man-
ner, and this response was markedly reduced in the absence
of MyD88. Heat-killed mycobacteria also induced IL-12p40
production, indicating that this response is not dependent on
DC infection. Nevertheless, in agreement with a previ-
ous study (44), 
 
M. tuberculosis
 
–induced IL-12 synthesis was 
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greatly impaired in the presence of cytochalasin D, suggest-
ing at least a partial requirement for bacterial phagocytosis
(Fig. 1 B). Interestingly, DCs from either TLR2- or TLR9-
deficient mice displayed significantly reduced IL-12p40 pro-
duction in response to live (Fig. 1 D) or heat-killed (not de-
picted) 
 
M. tuberculosis
 
, with TLR9-deficient DCs showing
the greater defect. However, DCs from mice lacking these
single TLRs were clearly less impaired in their IL-12 respon-
siveness than DCs from MyD88
 
 
 
/
 
 
 
 animals (Fig. 1 D).
Chloroquine partially inhibited bacterial-induced IL-12 syn-
thesis by WT DCs and completely blocked the response of
TLR2
 
 
 
/
 
 
 
 DCs to this stimulus (Fig. 1 C), supporting a ma-
jor requirement for endosomal acidification in 
 
M. tuberculosis
 
–
stimulated IL-12 production.
To test whether TLR9 and TLR2 have additive effects
on 
 
M. tuberculosis
 
–induced cytokine production, we gener-
ated TLR2/9-deficient mice and tested the response of
DCs from these double KO (DKO) animals. Importantly,
 
M. tuberculosis
 
–exposed splenic DCs from TLR2/9
 
 
 
/
 
 
 
 mice
displayed a profound reduction in IL-12p40 synthesis,
greater than that seen with either of the single KO animals
and comparable to that seen with DCs from MyD88-defi-
cient mice (Fig. 1 D). TLR2/TLR9 cooperation was also
observed in the IL-12p40 as well as p70 response of
BMDCs to 
 
M. tuberculosis
 
 (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20051782/DC1), al-
though in agreement with previously published data in a
similar in vitro system (43), levels of the IL-12 heterodimer
were much lower than the single p40 chain. Also consistent
with previous findings (45), no influence of TLR2, TLR9,
or MyD88 on type I IFN production (IFN-
 
 
 
) by DCs
stimulated with live 
 
M. tuberculosis
 
 was detected in these
experiments (Fig. S2 D).
Because macrophages play a major role in the response to
mycobacteria, we also investigated TLR2/TLR9 involve-
ment in proinflammatory cytokine production by these cells.
BMM from TLR2- or TLR9-deficient mice showed signifi-
cant reductions in bacteria-stimulated IL-12 synthesis (Fig. 2
A). Moreover, DKO BMM showed reduced cytokine re-
sponses comparable to those seen in MyD88
 
 
 
/
 
 
 
 APC popu-
lations (Fig. 2), suggesting that TLR2 and TLR9 act in con-
cert in signaling IL-12 responses by these cells. In contrast,
TNF and IL-6 production by macrophages appeared to be
controlled primarily by TLR2 and not TLR9 (Fig. 2, B and
C). TLR2 also appeared to preferentially regulate the low
level TNF response observed in BMDCs (Fig. S2 C) and
splenic DCs (not depicted).
Figure 1. Role for both TLR9 and TLR2 in the MyD88-dependent 
IL-12p40 response of splenic DCs to M. tuberculosis. (A) Purified CD11c  
spleen cells from WT or MyD88 /  mice were exposed to live (MOI   1:1 
[M. tuberculosis 1] or 3:1 [M. tuberculosis 3]) or heat-killed (MOI   1:1 
H-K M. tuberculosis 1]) M. tuberculosis for 24 h. (B) WT DCs were treated 
with 5  g/ml cytochalasin D or vehicle (DMSO) for 30 min and then incu-
bated with live M. tuberculosis (MOI   1:1) or 10  g/ml LPS for 24 h. 
(C) DCs from WT or TLR2 /  mice were treated with 5  g/ml chloroquine 
or vehicle (saline) for 30 min and then stimulated with live M. tuberculosis 
(MOI   1:1) for 24 h. (D) DCs from WT, MyD88 / , TLR2 / , TLR9 / , and 
TLR2/9 /  were exposed to live M. tuberculosis (MOI   1:1) or TLR ago-
nists as described in A. In all experiments, supernatants were harvested 
and IL-12p40 was determined by ELISA. Results are means   SE of tripli-
cate measurements. Experiments shown are representative of at least 
three performed. *, P   0.05 between experimental and control groups in 
A, B, and C. **, P   0.05 between TLR2 /  versus TLR9 /  values in D.
Figure 2. Role of TLR9 and TLR2 in proinflammatory cytokine 
production by M. tuberculosis–stimulated macrophages. BMM from 
WT, MyD88 / , TLR2 / , TLR9 / , and TLR2/9 /  were stimulated with 
M. tuberculosis (MOI   1:1), 15  g/ml CpG, 5  g/ml PGN, or 100 ng/ml 
LPS for 24 h. (A) IL-12p40, (B) TNF, and (C) IL-6 production was measured 
in the culture supernatants by ELISA. Results are means   SE of triplicate 
measurements. Experiments shown are representative of two performed. 
*, P   0.05 between WT versus KO values.TLR9 COOPERATES WITH TLR2 IN RESISTANCE TO M. TUBERCULOSIS | Bafica et al. 1718
TLR2 and TLR9 cooperate in host resistance 
to M. tuberculosis infection
To assess and compare the respective roles of TLR2 and
TLR9 in resistance to infection in vivo, we measured
survival, bacterial loads, and histopathology in TLR2 / ,
TLR9 / , TLR2/9 / , MyD88 / , and WT control mice
infected by the aerosol route with a low dose (50–100
CFUs) of virulent M. tuberculosis. At this challenge level,
all WT animals survived for at least 200 d, whereas all
MyD88 /  animals succumbed within 75 d as reported pre-
viously (20, 21). Most single TLR2 /  and TLR9 /  mice
survived for the full 200-d period of the experiment, with
some attrition occurring after day 100 (Fig. 3 A). In contrast,
infected TLR2/9 /  mice began to die much earlier, and all
succumbed within 120 d (Fig. 3 A).
In several previous studies, a more profound effect of
TLR2 deficiency on host resistance to M. tuberculosis was re-
vealed at higher challenge doses (23, 28). In analogous fash-
ion, TLR9-deficient mice were shown to be highly suscep-
tible to challenge with 500 CFUs/mouse, with all of the
animals now succumbing by day 70 (Fig. 4 A).
The observed effects of TLR deficiency on host resistance
correlated with changes in pulmonary bacterial load measured at
days 21 and 42 after infection with a low dose inocula (Fig. 3
B). Thus, as reported previously (20, 21), MyD88 /  mice
showed greatly increased bacterial burdens in comparison to
WT animals, a difference that approached 2 logs by day 42 after
infection. In contrast, the single TLR2 /  and TLR9 /  mice
showed only minor increases in mycobacterial loads at both
time points (Fig. 3 B), and it was only at day 100 after infection
that these differences in CFUs reached statistical significance
(not depicted). Importantly, at day 21 after infection, TLR2/
9 /  animals displayed increases in pulmonary bacterial counts
equivalent to those observed in the MyD88 /  mice, and at day
42, the TLR2/9 /  animals still maintained significantly higher
CFUs when compared with WT or each of the single TLR-
deficient mice, albeit lower than the bacterial counts in the
MyD88 /  animals (Fig. 3 B). Similar alterations in CFUs were
observed in the spleens from the same animals (not depicted).
Although single TLR9 /  mice challenged with a low dose of
M. tuberculosis failed to display significantly higher pathogen
loads than WT animals at days 21 and 42, they exhibited statisti-
cally significant increases in CFUs when challenged with the
higher dose (500 CFUs) inocula (Fig. 4 B), and this loss in resis-
tance correlated with diminished ex vivo IL-12p40 production
detected in lung homogenates (not depicted).
Figure 3. Interaction of TLR9 and TLR2 in host resistance to aerosol 
M. tuberculosis infection. (A) WT, TLR2-, TLR9-, TLR2/9-, and MyD88-
deficient mice were aerogenically infected with 50–100 CFUs/mouse (n   6 
animals per group), and survival was monitored. The results shown are 
representative of two independent experiments. Statistical analysis revealed 
that the MyD88-, TLR9-, and TLR2/9-deficient mice were significantly more 
susceptible (P   0.01) than WT animals and that the survival curve of the 
TLR2/9 /  mice is significantly different from that of the TLR9 (P   0.027), 
TLR2 (P   0.0053), or MyD88 (P   0.002) animal groups. (B) Lungs from 
infected animals were harvested at 21 and 42 d after infection, and myco-
bacterial loads were determined. Results are mean   SE of measurements 
from four animals. The experiment shown is representative of two performed. 
*, differences in CFUs between the KO versus WT groups that are statistically 
significant (P   0.05).
Figure 4. Increased susceptibility of TLR9 /  mice to high dose 
M. tuberculosis infection. (A) WT, MyD88-, and TLR9-deficient mice were 
aerogenically infected with 500 CFUs/mouse (n   5 animals per group) 
instead of the usual 50–100 CFU challenge, and survival was monitored. 
The results shown are representative of two independent experiments. 
Statistical analysis revealed that the MyD88- and TLR9-deficient mice 
were significantly more susceptible (P   0.001) than WT animals and that 
the survival curve of the TLR9 mice is significantly different (P   0.0042) 
from that of the MyD88 animal group. (B) Lungs from infected animals 
were harvested at 14 and 21 d after infection, and mycobacterial loads 
were determined. Results are mean   SE of measurements from four 
animals. *, a statistically significant difference (P   0.05) in CFUs between 
TLR9 /  versus WT mice.JEM VOL. 202, December 19, 2005 1719
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Cooperative effects of TLR2 and TLR9 on the pulmonary 
histopathologic response to M. tuberculosis
To determine whether the increased susceptibility of
TLR9 /  and TLR2/9 /  mice is reflected in the tissue re-
sponse to M. tuberculosis, we examined the lungs of the ani-
mals at day 42 after infection. As reported previously (20),
lungs from MyD88 /  animals exhibited widespread necro-
sis with few distinct granulomas (Fig. 5, B and G) and
showed marked increases in acid-fast–stained bacilli (Fig. 5
L) when compared with WT mice (Fig. 5, A, F, and K).
Also in agreement with previous studies (28), lungs from in-
fected TLR2 /  mice showed increased inflammation with
exuberant polymorphonuclear infiltrates, interstitial pneu-
monitis, and general disruption of granuloma morphology
(Fig. 5, C, H, and M).
In contrast, lungs from TLR9 /  mice showed no ma-
jor difference in overall histopathology (Fig. 5, D and I) or
granuloma numbers (not depicted) when compared with
lungs from similar infected WT animals. And like lungs
from TLR2 /  mice, lungs from TLR9 /  mice showed
only marginal increases in acid-fast–stained bacteria (Fig. 5,
K–N). However, a striking difference was seen in the lungs
of the day 42 infected TLR2/9 /  animals in comparison
with either of the single TLR-deficient or WT mice. Sec-
tions from the former animals displayed widespread inflam-
mation (Fig. 5, E and J), even more extreme than that seen
in the TLR2 /  mice (Fig. 5, C and H) and closely resem-
bling that observed in the MyD88 /  animals (Fig. 5, B
Figure 5. Lungs from TLR2/9 /  mice display exacerbated pulmo-
nary pathology and increased acid-fast bacilli. Formalin-fixed, paraffin-
embedded pulmonary tissue sections from day 42 infected mice were 
stained with hematoxylin and eosin (A–J). Note the increased inflammation 
in TLR2 /  and TLR2/9 /  lungs (A and E), with the more extreme pathology 
in the latter group. Acid-fast bacilli in lung tissue were stained with the 
Ziehl-Neelsen method (K–O). Representative sections from infected WT 
(A, F, and K), MyD88 /  (B, G, and L), TLR2 /  (C, H, and M), TLR9 /  (D, I, 
and N), and TLR2/9 /  (E, J, and O) mice are shown. Original magnification 
is 5 (A–E), 20 (F–J), and 10 (K–O).
Figure 6. Influence of TLR9 on the generation of IFN- –producing 
CD4  T cells and Th1-associated cytokines in M. tuberculosis–infected 
mice. (A) Lung cells isolated from day 30 infected mice were stimulated with 
anti-CD3 mAb, and intracellular IFN-  production was determined by flow 
cytometry after gating lymphocyte populations by forward and side scatter 
parameters. The FACS profiles of anti-CD4– and anti-CD8–stained lympho-
cytes in A are from pooled cells from two mice and are representative of 
results from four animals per group. The majority (85–95%) of the IFN-  plus 
CD4  cells shown in the dot plots in the top panel were determined to be 
CD8  T cells (unpublished data). Based on its nonspecific staining with 
multiple antibodies, the CD4 dim IFN-   population in the lung preparations 
from infected MyD88 KO mice is likely to represent dead cells, consistent with 
their abundance in sections of the same tissue (Fig. 5, B and G). Percentage of 
CD4  and CD8  T cells that stain positively for IFN-  calculated from the 
experiments shown in A. Relative expression of mRNAs for IFN-  (C) and 
IL-12p40 (D) determined in lungs at 30 d after infection. Results are mean   
SE of measurements from three animals. (E) Purified splenic CD4  T cells 
from the same mice described in A were cocultured with BMDCs infected 
with different MOIs for 72 h. IFN-  was assayed by ELISA in culture superna-
tants. The means   SE of measurements from triplicate wells are pre-
sented. The experiment shown was performed twice with similar results. 
*, significantly different values (P   0.05) between WT and KO cells.TLR9 COOPERATES WITH TLR2 IN RESISTANCE TO M. TUBERCULOSIS | Bafica et al. 1720
and G). Moreover, lungs from the TLR2/9 /  animals ex-
hibited focal necrosis, a process rarely seen in WT or single
TLR-deficient mice but common in MyD88 /  mice. In
addition, numerous acid-fast bacilli were clearly evident in
lung tissue from the double TLR-deficient hosts (Fig. 5
O), consistent with the increased pulmonary CFUs observed
in these animals (Fig. 3 B).
In contrast to TLR2, TLR9 controls IFN-  production 
by CD4  T cells in M. tuberculosis–infected animals
Because IL-12–dependent IFN-  is a major mediator of re-
sistance to M. tuberculosis and our data indicated a major in-
fluence of TLR9 on bacteria-induced IL-12 production in
vitro (Fig. 1 D), we asked whether defects in in vivo IFN- 
responses are also evident in TLR9 as well as in TLR2/9 / 
mice. When measured at 30 d after infection by intracellular
cytokine staining after ex vivo anti-CD3 stimulation,  40%
of pulmonary CD4  cells from WT animals were found to
secrete IFN- , and this response was diminished by 60–70%
in the equivalent population from MyD88 /  mice (Fig.
6, A and B). Importantly, TLR9 /  and TLR2/9 /  but
not TLR2-deficient mice showed significant reductions in
IFN-   CD4  cells as well as in lung IFN-  and IL-12p40
mRNA expression, although the observed decreases were
less than those seen in MyD88 /  mice (Fig. 6, B–D). In
contrast, none of the KO mice showed deficiencies in
IFN-   CD8 cells (Fig. 6 B), and it is possible the retention
of this cell population in the TLR9 /  and TLR2/9  contrib-
utes to their partial resistance. Measurement of changes in
IL-12p70 production was not possible because the het-
erodimer is not present in sufficient quantity in sera or lung
homogenates to allow detection by ELISA.
To confirm that these differences reflect alterations in M.
tuberculosis–specific Th1 priming, we tested the recall re-
sponses of splenic CD4  T cells from day 30 infected mice
using BMDCs from WT mice that had been infected in
vitro with different doses of live mycobacteria as APCs. As
shown in Fig. 6 E, major defects in M. tuberculosis–specific
IFN-  responses were observed in the TLR9 / , MyD88 / ,
and TLR2/9 /  mice but not in the TLR2 /  animals.
DISCUSSION
The greatly enhanced susceptibility of MyD88 /  mice to M.
tuberculosis is perhaps the strongest evidence for a role of TLR/
IL-1R signaling in host resistance to this pathogen. Neverthe-
less, in previous studies it has been difficult to assign this defect
to the role of any individual TLR/IL-1R family member. Be-
cause mice deficient in each of the known TLRs have not yet
been systematically screened, the possibility remains that one
yet-to-be-investigated TLR accounts for MyD88-dependent
resistance. An alternative explanation proposed by others (2,
46) as a general concept for TLR function is that multiple
TLRs act in concert in determining pathogen control. In this
study, we have identified a previously unrecognized TLR–
ligand interaction that contributes to the innate and adaptive
immune response to M. tuberculosis and provided clear-cut ev-
idence for its cooperation with a second TLR signal in host
resistance to this bacterium.
Although mycobacterial DNA has long been linked to
the adjuvant properties of BCG as well as mycobacterial ex-
tracts (34–36), it is only with the recent discovery of immu-
nostimulatory CpG motifs (31) and their recognition by
TLR9 (47) that the basis of this effect of mycobacteria on
the immune system has been properly appreciated. Never-
theless, the role of TLR9/DNA interaction on host resis-
tance to M. tuberculosis or to other medically important
mycobacteria has never been systematically examined. The
findings presented here confirm that mycobacterial DNA
does indeed stimulate proinflammatory cytokine synthesis
through TLR9 and further establish a role for this TLR in
the IL-12 and Th1 responses to live M. tuberculosis in vitro as
well as in vivo. Although these defects were associated with
only minor increases in pulmonary bacterial loads and de-
creases in host survival at low dose challenge, TLR9 / 
mice displayed markedly enhanced susceptibility when ex-
posed to higher dose bacterial inocula (Fig. 4) as described
previously for TLR2 /  animals (23, 28). However, in di-
rect contrast to TLR2 /  mice, infected TLR9 /  animals
did not show major alterations in granulomatous pathology
or in vitro TNF production by APCs. Thus, although
TLR9 /  and TLR2 /  mice show comparable changes in
resistance to M. tuberculosis infection at both low and high
dose infection, they exhibit distinct immune response defects
to this pathogen in vivo.
It is likely that TLR9 triggering by mycobacteria requires
bacterial uptake and phagolysosomal fusion, as drugs that in-
hibit these two processes dampened the TLR9-dependent
IL-12 response of APCs. Therefore, we hypothesize that M.
tuberculosis triggers TLR9 by releasing DNA from either bac-
teria dying within phagolysosomes or through the uptake of
dead bacilli. An alternative possibility that cannot be ruled
out at present is that mycobacteria possess TLR9 ligands dis-
tinct from genomic bacterial DNA. A recently described
precedent is the stimulation of TLR9 by hemozoin pigment
from malaria (48).
Although TLR9 alone had distinct but partial effects on
host resistance to M. tuberculosis, these were clearly enhanced
in mice doubly deficient in TLR9 and TLR2 as reflected in
both increased bacterial load and reduced mean survival. In
addition, DCs from TLR2/9 DKO mice showed greater im-
pairment in their mycobacteria-induced IL-12 responses than
did the equivalent populations from each of the single
TLR /  animals. In each of the above parameters, the ob-
served effects of the absence of TLR9 and TLR2 appeared to
be additive in the TLR2/9 DKO mice, although the pulmo-
nary pathology and bacterial burden in these animals as mea-
sured by both CFU and acid-fast bacilli in situ staining
showed evidence of synergy (Figs. 3 and 5, M–O). Never-
theless, in terms of the other parameters analyzed, the phe-
notype of the TLR2/9 DKO animals is more complex.
For example, redundancy was observed in the regulation of
IL-12p40 production by TLR2 and TLR9 in BMDCs (Fig. S2JEM VOL. 202, December 19, 2005 1721
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A). Moreover, as discussed above, in several cases individual
immune deficiencies appeared to be linked to single TLRs.
For example, M. tuberculosis–induced TNF production ap-
pears to be controlled by TLR2 and recall IFN-  responses
by TLR9.
It has recently been proposed in several studies (46, 49)
that TLR signals synergize in the triggering of IL-12 and
other Th1-promoting mediators by DCs. This hypothesis,
based largely on experiments examining the interactions of
multiple TLR ligands on DC responses, argues that the in-
duction and maintenance of an effective immune response
against microbes depends on the recognition of a “pathogen
code” by a combination of different TLRs. Our results par-
tially support this concept because some but not all of the M.
tuberculosis–induced TLR effects were synergistic in vivo.
Nevertheless, it is likely that specific combinations of TLRs
act in concert by instead stimulating distinct responses that
together are required for effective microbial control, a mech-
anism also requiring a pathogen code. This mechanism also
would depend on induction thresholds related to both the
dose and kinetics of infection.
Although our in vivo data reveal a major cooperative in-
teraction between TLR9 and TLR2 in host resistance to
mycobacteria, this is clearly not the case for other TLR
combinations. Thus, TLR2/4 /  mice have been found to
display unimpaired resistance to M. tuberculosis as well as
BCG infection (45, 50). Moreover, in a recent experiment,
we failed to observe increased susceptibility to M. tuberculosis
in animals deficient in TIRAP, an adaptor molecule required
for MyD88-dependent signaling by both TLR2 and TLR4,
relative to mice singly deficient in TLR2 (unpublished data).
It is of interest that both TLR2 /  and TLR9 /  mice dis-
play clearly enhanced susceptibility to high dose M. tuberculo-
sis infection, a property that does not appear to be shared
by TLR4 /  animals (23). This observation suggests that
screening of different TLR/IL-1R–deficient mice by high
dose challenge could be used as a strategy for detecting addi-
tional signaling receptors that cooperate with TLR2 and
TLR9 in explaining the MyD88-dependent control of M.
tuberculosis infection. Having shown cooperation between
two TLR/IL-1R family members in host resistance to this
pathogen, the next obvious step is to determine whether
even greater effects on control of M. tuberculosis will be evident
in mice with the appropriate triple receptor deficiency.
The findings of this study in the murine tuberculosis
model have several implications for the investigation of the
role of TLR/IL-1R in susceptibility of humans to mycobac-
terial infection and disease. The involvement of these recep-
tors has been suggested from genetic studies correlating sin-
gle nucleotide polymorphisms within the TLR2 gene, with
disease severity in patients infected with M. leprae (51) or
susceptibility to infection in populations exposed to M. tuber-
culosis (52, 53). Our observations that TLR9 also contributes
to host resistance to mycobacterial infection suggests that
polymorphisms in this gene (e.g., TLR9 single nucleotide
polymorphisms at  1,237 and  2,428; reference 54) should
also be examined in the same type of genetic study and pre-
dicts that more extreme disease susceptibility will be seen in
patients with simultaneous mutations in both TLR2 and
TLR9. At a more general level, the evidence that different
TLRs cooperate in determining host resistance to infection
in murine experimental models supports the notion that
complex polygenic analyses involving the interaction of
multiple rather than single TLR gene family alleles might be
required to reveal major functions for the TLR/IL-1R system
in innate immunity to human infectious diseases.
MATERIALS AND METHODS
Experimental animals. WT control C57BL/6 mice were purchased
from Taconic Farms. Breeding pairs of MyD88 / , TLR2 / , and
TLR9 /  mice were obtained from S. Akira (Osaka University, Osaka,
Japan) via D. Golenbock (University of Massachusetts Medical School,
Worcester, MA) and R. Seder (National Institutes of Health [NIH], Be-
thesda, MD). The MyD88 /  and TLR9 /  mice had been backcrossed
to C57BL/6 for 10 generations, and the TLR2 /  animals had been back-
crossed for five generations. TLR2/9 / animals were generated by mat-
ing TLR2 /  with TLR9-deficient animals. These F1 animals were then
intercrossed to derive homozygous TLR2/9 /  mice identified by PCR
of tail snips (unpublished data). Because of the known influence of 129/
SvJ genes in host resistance to intravenous M. tuberculosis infection (55)
and the finite although remote possibility that the relevant genes may have
been retained in the TLR2 /  parents of this cross, we compared the re-
sistance of C57BL/6 and B6/129F2 mice under the conditions of low
dose aerosol infection used. In agreement with studies by other investiga-
tors (56–59), we observed no significant differences in survival and bacte-
rial loads between the two mouse groups (unpublished data). Animals
were bred and maintained at an American Association of Laboratory Ani-
mal Care–accredited facility at the National Institute of Allergy and Infec-
tious Diseases [NIAID], NIH. Mice of both sexes between 8- and 14-wk
old were used in all experiments.
TLR agonists and other reagents. The synthetic lipoprotein Pam3Cys
(S-[2,3-bis(palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-
Lys4-OH, trihydrochloride) was obtained from EMC Microcollections. Pep-
tideoglycan (Staphylococcus aureus), ultra-pure LPS (E. coli 0111:B4), endo-
toxin-free E. coli DNA (K12), and CpG oligo DNA (1826) were purchased
from Invivogen. Purified genomic DNA from M. tuberculosis H37Rv was
provided by J. Belisle (Colorado State University, Fort Collins, CO) under
the NIH, NIAID contract NO1 AI-75320 “Tuberculosis Research Materials
and Vaccine Testing.” Purified genomic DNA from Mycobacterium sp (BCG)
was purchased from American Type Culture Collection (no. 19015D).
Chloroquine and cytochalasin D were obtained from Sigma-Aldrich.
APCs and cell cultures. Splenic CD11c  cells were obtained by incuba-
tion of splenic cell suspensions with anti-CD11c MicroBeads (Miltenyi Bio-
tec) for 15 min at 4 C followed by a washing step in PBS/bovine serum al-
bumin and then sorted in an AutoMACS (isolation mode POSSEL_S;
Miltenyi Biotec). Analysis of the sorted cells showed purity  95%.
BMDCs were generated as originally described elsewhere (60). In brief,
BM cells were removed from the femurs and tibias of mice and cultured in
RPMI 1640 (GIBCO BRL) supplemented with 2 mM l-glutamine, heat-
inactivated 10% FCS, 100  g/ml penicillin, 100  g/ml streptomycin, 5  
10 5 M 2-mercaptoethanol (complete media; all from Sigma-Aldrich), plus 20
ng/ml GM-CSF (GIBCO BRL). On days 3 and 6, complete media was added
containing 10 ng/ml GM-CSF. BMDCs were used at days 6–7 of culture.
BMM were generated as described previously (61). In brief, BM cells
were washed and resuspended in DMEM containing glucose, supplemented
with 2 mM L-glutamine, 10% FCS, 10 mM Hepes, 100  g/ml streptomy-
cin, 100 U/ml penicillin (all from Sigma-Aldrich), and 20–30% L929 cell-TLR9 COOPERATES WITH TLR2 IN RESISTANCE TO M. TUBERCULOSIS | Bafica et al. 1722
conditioned medium (as a source of M-CSF), and incubated for 7 d at
37 C, 5% CO2.
M. tuberculosis infections. For in vitro exposure of APCs to M. tuberculosis,
the virulent strain H37Rv was prepared from frozen stocks as described previ-
ously (62). In some experiments, mycobacteria were killed by heating at 60 C
for 1 h. DCs and BMM were exposed to different multiplicities of infection
(MOIs) of mycobacteria or TLR agonists in complete media for 18–24 h. In
one set of experiments, splenic DCs were first preincubated with 5  g/ml
chloroquine or cytochalasin D for 30 min at 37 C. Cells were then exposed
to mycobacteria (MOI   1) or 10  g/ml LPS as a control. Supernatants were
then harvested, and ELISAs for IL-12p40, TNF, and IL-6 (R&D Systems) as
well as for IFN-  (PBL Biomedical Laboratories) were performed.
For in vivo mycobacterial infection, mice were infected as described
previously (58). In brief, animals were placed in a closed, nose-only aero-
solization system (CH Technologies) and exposed for 15 min to nebulized
M. tuberculosis to deliver 50–100 bacteria/mouse (low dose inocula). In a
different set of experiments, mice were infected with  500 bacteria/mouse
(high dose inocula). To assess mycobacterial load, lungs and spleens were
harvested at several times after infection, and tissue homogenates were di-
luted in PBS/Tween-20 and cultured on 7H11 agar plates as described
previously (63). Colony counts were determined 21 d later.
Flow cytometry. Single cell suspensions from individual mice were im-
munostained as described previously (15). In brief, for intracellular detec-
tion of IFN- , total lung cells were stimulated with 10  g/ml of plate-
bound anti-CD3 at 37 C for 6 h, and brefeldin A was added during the last
2 h. Cells were then surface stained with mAb to CD4 (clone RM4-5) or
CD8 (clone 53-6.7), fixed, and permeabilized. Intracellular IFN-  was de-
tected with anti–IFN-  mAb (clone XMG1.2). Data were collected using a
FACSCalibur (BD Immunocytometry Systems) with CELLQuest (BD Bio-
sciences) and analyzed with FlowJo software (Tree Star). All mAbs were
obtained from BD Biosciences.
Measurement of cytokine gene expression in lung tissue. Total
RNA was isolated from lungs, and real-time RT-PCR was performed on
an ABI Prism 7900 sequence detection system (Applied Biosystems) using
SYBR Green PCR Master Mix (Applied Biosystems) after RT of 1  g
RNA using Superscript II reverse transcriptase (Invitrogen). The relative
level of gene expression was determined by the comparative threshold cycle
method as described by the manufacturer, whereby each sample was nor-
malized to hprt and expressed as a fold change compared with untreated
controls. The following primer pairs were used: for hprt: GTTGGTTA-
CAGGCCAGACTTTGTTG (forward) and GAGGGTAGGCTGGC-
CTATAGGCT (reverse); il-12p40: CTCACATCTGCTGCTCCA-
CAAG (forward) and AATTTGGTGCTTCACACTTCAGG (reverse);
ifn- : AGAGCCAGATTATCTCTTTCTACCTCAG (forward) and
CTTTTTTCGCCTTGCTGCTG (reverse).
CD4  T cell recall response assay. Spleen cells from M. tuberculosis–
infected WT, MyD88 / , TLR2 / , TLR9 / , and TLR2/9 /  mice were
incubated with anti-CD4 MicroBeads (Miltenyi Biotec) for 15 min at 4 C,
washed, and then sorted in the AutoMACS (Miltenyi Biotec). The purified
CD4  T cells (106 cell/ml) were then cocultured with M. tuberculosis–
infected BMDCs (5   105 cells/ml) for 72 h. In parallel, 10  g/ml of plate-
bound anti-CD3– (clone 145-2C11; BD Biosciences) stimulated CD4  T
cells were cultured for 72 h as a positive control. IFN-  (R&D Systems)
levels in culture supernatants were then determined by ELISA.
Histopathology. Lungs were fixed by inflating the tissues with neutral
buffered formalin, sectioned, and then stained with hematoxylin and eosin
or by the Ziehl-Neelsen method to detect acid-fast mycobacteria.
Statistics. Student’s t test was used to determine the significance of differ-
ences between groups. Survival curves were generated using the Kaplan-
Meier method, and the significance of differences was calculated by the log-
rank test. Values of P   0.05 were considered statistically significant.
Online supplemental material. Fig. S1 demonstrates the TLR9 depen-
dence of proinflammatory cytokine responses by APCs stimulated with my-
cobacterial DNA. Fig. S2 demonstrates a marked decrease in M. tuberculosis–
stimulated IL-12 but not TNF production by TLR2/9 /  BMDCs when
compared with the equivalent cell populations from single TLR /  or WT
animals. Fig. S3 shows that M. tuberculosis–stimulated type I IFN (IFN- )
production by DCs does not require TLR2, TLR9, or MYD88 in contrast
with the TLR9/MyD88 dependence of the same cytokine response stimu-
lated by mycobacterial DNA. Figs. S1–S3 are available at http://www.
jem.org/cgi/content/full/jem.20051782/DC1.
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